JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

NCT05194995 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Colorectal Cancer
Small Intestinal Cancer
Appendiceal Cancer

Interventions

DRUG: JAB-21822
DRUG: Cetuximab

Sponsor

Allist Pharmaceuticals, Inc.